Pfizer Safety Document and Remdesivir
This request has an unknown status. We're waiting for Chuck Schooner (Account suspended) to read a recent response and update the status.
From: Chuck Schooner (Account suspended)
Dear Ministry of Health,
Please state if the following report was used in the assessment to approve the Pfizer/Biontech vaccine when Medsafe first approved this gene therapy/vaccine.
5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT
REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021
If the report was not available can you please state if Medsafe requested any real time safety reports from Pfizer in advance of approving this gene therapy.
By the time Medsafe approved this gene therapy the vaccine had been widely used globally and so there would be real time statistics. If not, did you rely on Pfizer trial information only?
Medsafe then approved the gene therapy for two more years and stated Pfizer had met a number of safety conditions following their provisional approval. Please provide all reports/evidence that Pfizer provided Medsafe that prove that they met their safety conditions that were part of the first gazette notice.
The above report was dated early 2021 - please state if Pfizer had provided this to Medsafe at all when they have completed any of their due diligence in assessing this gene therapy.
Please state if on the release of the documents by the FDA has Medsafe requested all of the Pfizer documents that have been released - please provide a list of all the Pfizer documents that Medsafe have relied upon in approving this gene therapy.
This document is now available and if you approve this in children who will ultimately be responsible for illnesses in children? Medsafe or Ministry of Health.
Were Medsafe responsible for approving Remdesivir as a Covid-19 treatment.
Is Medsafe/Ministry of Health using Remdesivir as a Covid-19 treatment?
What studies were used to say Remdesivir was safe?
An Ebola study using Remdesivir showed that it was pulled from use in a 12 month trial after six months because it killed 54% of the trial subjects it used.
The Remdesiver study also showed that patients were having the following side effects
- 10 day treatment of Covid-19 showed 23% had serious adverse events were organ dysfunction syndrome, septic shock, acute kidney failure and kidney failure.
Please state how many Covid patients have been treated with Remdesiver in New Zealand and how many of them had the above side effects and died. It appears Remdesiver will kill you. Did Medsafe do any due diligence for Remdesiver as it will likely poison patients.
From: OIA Requests
Thank you for your Official Information Act (the Act) request. This is
an automatic reply to let you know we received it.
Due to the COVID-19 global pandemic response, the Ministry is experiencing
significantly higher volumes of queries and requests for information. We
will endeavour to acknowledge your request as soon as possible. Further
information about COVID-19 can be found on our
Please be advised that due dates for requests received from 29 November
2021 onwards take into account the following periods:
Christmas (25 December 2021)
Summer Holidays (25 December to 15 January)
New Year's Day (1 January 2022)
Day after News Year's Day (2 January 2022)
If you'd like to calculate the due date for your request, you can use the
Ombudsman's online calculator here: http://www.ombudsman.parliament.nz/
If you have any questions while we're processing your request, please let
us know via [email address]
OIA Services Team
Ministry of Health information releases
Unite against COVID-19
3. mailto:[email address]
From: OIA Requests
Kia ora Chuck
Please find attached a response to your requests for official information.
Office of the Director-General | Ministry of Health
E: [email address]
Do your bit to keep New Zealand COVID free; get vaccinated; wear a mask;
practice good hygiene (includes washing your hands often and coughing into
your elbow), sign using the NZ COVID Tracer app, if you’re unwell stay
home and get tested.
1. mailto:[email address]